Seegene and Werfen have signed an agreement to use the former’s OneSystem business to develop syndromic qPCR assays for Spanish and Portuguese healthcare systems.
The agreement will help advance talks to expand their current collaboration for the Spanish and Portuguese markets through the OneSystem business.
Both entities are currently engaged in talks for the co-development of qPCR assays at Werfen’s OEM Technology Center in Spain.
The partnership will focus on developing assays for drug resistance and sexually transmitted infections.
These talks started after Seegene signed an agreement in March with Israel-based diagnostic company Hylabs.
Werfen OEM chief operating officer José Luis Zarroc said: “We are excited about the possibility of strengthening our partnership with Seegene and we look forward to developing assays which are tailor-made for Spain and Portugal.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe OneSystem business’ syndromic quantitative PCR technologies, along with Seegene’s digitalised development system, will be used to develop assays.
Seegene will also offer automated manufacturing technologies for producing syndromic PCR assays, which are compatible with the company’s OneSystem instruments.
Seegene CEO Dr Jong-Yoon Chun said: “We will share our PCR technologies and know-how with any company in any country wishing to develop syndromic quantitative PCR assays.
“We aspire to develop PCR diagnostic assays for all diseases so that the world free from diseases would come closer.”
